Quick Answer
Summit Therapeutics Inc. reported Operating Income Loss of -$226.00 million for the year ending 2024.
- Summit Therapeutics Inc. showed an increase of +62.9% in Operating Income Loss from 2023 to 2024.
- This data is from Summit Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2025.
- XBRL data for this metric is available from 2019 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2024), Summit Therapeutics Inc.'s Operating Income Loss has declined by 4,293.7%.
- Historical annual values: Fiscal year 2024: -$226.00 million | Fiscal year 2023: -$609.65 million | Fiscal year 2022: -$72.09 million | Fiscal year 2021: -$86.19 million | Fiscal year 2020: -$53.19 million | Fiscal year 2019: -$27.47 million | Fiscal year 2019: $5.39 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: